IP Library Granted Patent US 9,320,719
Granted Patent B2
US 9,320,719 · App. 14/294,636 · Granted Apr 26, 2016

Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same

Inventors: Phillip B. Messersmith (Clarendon Hills, IL); Kvar C. L. Black, IV (Evanston, IL); Ji Yi (Evanston, IL); Jose G. Rivera (Waukegan, IL)
Assignee: Northwestern University
A61K9/51A61K9/0092A61K9/5094A61K31/69A61K33/00A61K33/26A61K33/38A61K39/39558A61K39/40A61K41/0052A61K41/0057A61K45/06A61K47/48861A61K49/1857A61N5/062B82Y5/00B82Y40/00C07K16/00G01N21/4795G01N21/554G01N33/587
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,719
App. No.
14/294,636
Granted
Apr 26, 2016
Kind
B2
Abstract

The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Claims (14)

1. A method for treating cancer comprising administering to a patient having cancer cells one or more nanoparticles comprising:

(a) a metallic core consisting essentially of gold and having a length along each axis of from 1 to 100 nanometers;

(b) a coating comprising polydopamine disposed on at least part of the surface of the metallic core; and

(c) one or more cetuximab anti-cancer cell surface receptor antibodies;

whereby the one or more nanoparticles target the cancer cells and the cancer is effectively treated, and wherein the cancer is selected from the group consisting of metastatic colorectal cancer, head and neck cancer, and epidermal growth factor receptor (EGFR)-expressing breast cancer.

2. The method of claim 1 , wherein the one or more nanoparticles further comprise an additional anti-cancer agent bound to the coating.

3. The method of claim 2 , wherein the anti-cancer agent is a proteasome inhibitor.

4. The method of claim 1 , further comprising the step of exposing the nanoparticles to light.

5. A method for treating cancer, the method comprising:

administering to a patient having cancer cells one or more nanoparticles comprising:

(a) a metallic core consisting essentially of gold and having a length along each axis of from 1 to 100 nanometers;

(b) a coating comprising polydopamine disposed on at least part of the surface of the metallic core; and

(c) one or more cetuximab anti-cancer cell surface receptor antibodies; and

exposing the nanoparticles to light, whereby the one or more nanoparticles target the cancer cells and the cancer is effectively treated, and wherein the cancer is selected from the group consisting of metastatic colorectal cancer, head and neck cancer, and epidermal growth factor receptor (EGFR)-expressing breast cancer.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 13, 2015
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036099/0277 →
Continuity (3)
Division 13420189 · Mar 14, 2012
Provisional Application 61453054 · Mar 15, 2011
Related Publication 20140271889A1 · Sep 18, 2014